TCT-424: Do Women Continue to have Longer Door-to-Balloon Times in the Era of STEMI Systems?  by unknown
TUESDAY, NOVEMBER 8, 2011, 8:00 AM - 10:00 AM
the independent predictors of 3 year adverse events.
Independent Predictors of 3-year MACE, Death and MI in Women
Conclusion: In the HORIZONS-AMI study smoking was an independent predictor of
MACE, death and reinfarction in women after acute myocardial infarction. Diabetes
was a predictor for MACE and reinfarction.
TCT-421
The SPIRIT WOMEN Single Arm Study: Two Year Follow-up Results
Marie-Claude Morice1, Stephan Windecker2, Maria Grazia Modena3, Ghada
Mikhail4, Fina Mauri5, Ruth Strasser6, Liliana Grinfeld7
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Background: The SPIRIT Women Study provides a characterization of the female
population undergoing stent implantation with emphasis on the evaluation of the safety
and efficacy of the XIENCE V Everolimus Eluting Coronary Stent (EES) (Abbott
Vascular, Santa Clara, USA).
Methods: The SPIRIT Women Single Arm Study is a prospective, open label study
designed to assess outcomes, when EES is used in females in a real-world situation.
Results: A total of 1,572 women with coronary artery disease undergoing percutaneous
coronary intervention were enrolled at 73 international sites between July 2007 and
March 2009. Patients suitable to be treated with up to 4 planned stents, reference vessel
diameter between 2.25 mm and 4.0 mm and lesion length of ≤ 28 mm were eligible,
including patients with acute coronary syndromes. Patients with a previously implanted
stent within the target vessel were excluded. The patient population included 34%
diabetics, 64% and 78% requiring medication for hypercholesterolemia and
hypertension respectively. The mean pre-procedure percent diameter stenosis was 83%
with 29% of lesions ≥ 20mm in length. The mean number of target lesions treated was
1.4. At 1 year, the primary endpoint of all death, myocardial infarction and target vessel
revascularization was 11.9%. One year results included stent thrombosis rate (0.59 %
definite and probable), cardiac death (0.8%), and TLR (2.4%).
Conclusion: This study represents the longest term outcome for EES reported to date
on a large ‘real world’ female population of patients outside of the United States. Two
year follow up rate for the study is 95%. Final adjudication of all clinical events is
ongoing. The 2 year clinical results of the SPIRIT Women Single Arm Study will be
presented and discussed.
TCT-422
Non-atherosclerotic coronary artery disease in young women
Jacqueline Saw, Andrew Starovoytov, John Mancini, Christopher Buller
Cardiology, Vancouver General Hospital, Vancouver, Canada
Background: Non-atherosclerotic CAD (NACAD) is an important cause of MI in
young women, but is often missed on coronary angiography. Our group previously
described the angiographic appearance of coronary fibromuscular dyplasia (FMD), but
the prevalence of this and other NACAD in young women have not been described.
Methods: We retrospectively reviewed all women aged ≤50 who underwent coronary
angiography at Vancouver General Hospital from April 1/2010 to April 30/2011. The
baseline characteristics and medication use were recorded. The angiograms were
reviewed meticulously and reported as normal or mild CAD (<30% stenosis),
atherosclerotic CAD (ACAD), or NACAD. NACAD is further characterized as
coronary dissection, coronary FMD (abrupt transition to diffuse obliterative disease
from a mid to distal coronary artery), ectasia, vasculitis, embolism, congenital anomaly,
or unclear etiology.
Results: Of 4318 coronary angiograms performed, 99 were done in women ≤50. The
mean age was 45±5 (range 31-50), average BMI 27, 19% had diabetes, 37%
dyslipidemia, 40% hypertension, 14% smokers, and 30% had ischemia on stress tests.
The majority (64) had acute coronary syndrome (ACS), and 41 had elevated troponin.
There were 49 with normal or mild CAD (2 Takotsubo cardiomyopathy), and 25 had
ACAD. Twenty (20.2%) had NACAD, of which 14 had coronary dissection or FMD
(13 had ACS). Four had spontaneous coronary dissection: 3 proven on optical
coherence tomography, and a 11 months post-partum retrograde dissection into left
main requiring CABG. Ten had diffuse mid-distal disease consistent with coronary
FMD (could not exclude concurrent coronary dissection), 9 had elevated troponin, and
4 had FMD in another vascular territory. Less common NACAD were suspected
vasculitis in 2 (pulmonary aspergillosis plus eosinophilia, and SLE), and coronary
ectasia in 4 women. Three women with ACS had disease that could not be distinguished
between ACAD or NACAD. Among women with elevated troponin ACS (41/99): 12
(29.3%) had normal or mild CAD (2 Takotsubo), 10 (24.4%) had ACAD, 16 (39.0%)
had NACAD [12 (29.3%) had coronary dissection or FMD, 2 vasculitis, and 2 ectasia],
and 3 had unclear etiology.
Conclusion: Non-atherosclerotic CAD is seen frequently among young women
undergoing coronary angiography, particularly those presenting with MI. Coronary
dissection or FMD is the most commonly encountered NACAD in young women, and
should be better characterized to avoid missed diagnosis.
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Background: Although young women are at low risk for developing atherosclerosis,
they may be at high risk for recurrent events once CAD is evident. There are limited
data on medium-term outcomes in young women undergoing PCI.
Methods: We evaluated 3797 women undergoing PCI enrolled in the NHLBI Dynamic
Registry and compared demographic and angiographic data, in-hospital and 1 year
outcomes in women <50 years (n=394) with women ≥50 years old (n=3403).
Results: Compared to women ≥ 50, younger women had lower rates of diabetes (31.9
vs. 38.3%, p=0.01), hypertension (61.4 vs. 79.0%, p<0.001), and hyperlipidemia (62.9
vs. 70.4%, p=0.003) but were more likely to be black (25.6 vs. 15.7%, p<0.001) and
current smokers (52.6 vs. 19.1%, p<0.001). In-hospital adverse event rates for younger
compared to women ≥ 50 were lower or equivalent (death 0.3 vs. 1.5%, p=0.04, MI
1.3 vs. 2.2%, p=0.22, CABG 0.8 vs. 1.0%, p=0.65). Despite less extensive CAD in
younger compared to women ≥ 50 (mean significant lesions 2.2 vs. 2.9, p<0.001),
women <50 were more likely to require repeat revascularization at 1 year (figure).
One-year adjusted relative risks (RR) for younger women using women ≥ 50 as the
reference are: death 0.4 (95% CI 0.2-0.9, p=0.03), CABG 2.2 (95% CI 1.5-3.3,
p<0.001), repeat PCI 1.9 (95% CI 1.5-2.5, p<0.001), and TVR 2.1 (95% CI 1.5-2.8,
p<0.001).
One Year CABG/Repeat PCI Rates for the Dynamic Registry Women
Conclusion: Despite fewer risk factors and less extensive CAD, younger women have
higher repeat revascularization rates after PCI. Plausible explanations include 1) higher
prevalence of smoking, 2) aggressive surveillance or 3) aggressive atherosclerotic and
restenotic phenotypes in young women.
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Do Women Continue to have Longer Door-to-Balloon Times in the Era of
STEMI Systems?
Melissa Blondeau, Michel Le May, Derek So, Chris Glover, Michael Froeschl, Jean-
François Marquis, Edward O’Brien, Alexander Dick, Marino Labinaz
University of Ottawa Heart Institute, Ottawa, Canada
Background: Prior studies suggest that women presenting with STEMI have longer
door-to-balloon times. We sought to determine if gender differences persists within the
context of a regional primary PCI program.
Methods: We identified pts referred for Primary PCI from the University of Ottawa
Heart Institute STEMI database. We compared baseline demographics, door-to-balloon
times, and hospital mortality in men and women. Logistic regression analysis was
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performed to determine if gender was an independent predictor of guideline door-to-
balloon time of <90 min.
Results: Amongst 2032 pts with confirmed STEMI referred between May 2005 and
July 2010, 574 (28%) were women and 1458 (72%) were men. Women differed from
men in the following baseline characteristics: age, 68±14 vs. 60±12, p<0.0001,
hypertension, 58% vs. 45%, p<0.0001, smoking, 34% vs. 44%, p<0.0001, prior bypass
surgery, 2% vs. 4%, p=0.01, prior stroke, 9% vs. 6%, p=0.01, systolic blood pressure,
132±30 vs 136±29, p=0.001, BMI, 27±6 vs. 28±5, p=0.02, creatinine clearance, 65±28
vs. 76±29, p<0.0001, and Killip class 1 82% vs. 87%, p=0.008. Women were more
likely to call for an ambulance, 71% vs. 62%, p=0.0001. PCI was performed in 92%
of women and 94% of men, p=0.17. Women were less likely to be treated with stents,
88% vs. 92%, p=0.007. The median door-to-balloon time in women was 105 min
(IQR=79-137) vs. 99 min (IQR= 72-132) for men, p=0.005. The 30 day mortality was
7.5% in women vs. 4.8% in men, p=0.02. The results of the multivariable analysis to
determine predictors of door-to-balloon time <90 min are shown in the table.
Conclusion: In spite of standardized protocols implemented in a STEMI system,
women continue to have longer door-to-balloon times. Additional research is needed
to reduce delays to reperfusion in women.
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(Abstract nos 426 - 436)
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Diabetes Mellitus Requiring Insulin and High Residual Platelet Reactivity After
Clopidogrel Loading Dose are Predictors of Long-term Clinical Outcome in
Patients with Acute Coronary Syndrome: the RECLOSE2-ACS Diabetes
Mellitus Substudy
Renato Valenti, Angela Migliorini, Guido Parodi, Rossella Marcucci, Piergiovanni
Buonamici, Giampaolo Cerisano, Rosanna Abbate, Gianfranco Gensini, David
Antoniucci
Division of Cardiology, Careggi Hospital, Florence, Italy
Background: The Responsiveness to CLOpidogrel and Stent-related Events in patients
with ACS(RECLOSE2-ACS) receiving PCI and for whom platelet reactivity after
clopidogrel loading was prospectively assessed. To test if high residual platelet
reactivity (HRPR) would be a prognostic marker of risk of thrombotic events and to
assess the relationship of diabetes mellitus (DM) with HRPR on clinical outcome.
Methods: Consecutive ACS patients undergoing PCI and platelet reactivity after 600
mg clopidogrel loading dose. Patients with HRPR (ADP 10 μmol ≥ 70%) received an
increased chronic dose of clopidogrel. DM was investigated according to insulin use.
The interaction between DM and HRPR on outcome was assessed by Cox analysis.
Primary end point: composite of cardiac death, MI, urgent PCI, and stroke at 2y FU.
ClinicalTrial.gov: NCT01231035.
Results: A total of 1789 patients were enrolled: 20% had DM: 11% were non-insulin
dependent (NIDD), 9% were insulin dependent (IDD) and 80% were non diabetic
(ND). HRPR incresead according to diabetic status: ND 12%, NIDD 18% and IDD
22% (p=.001). Most patients with HRPR remained with an ADP ≥ 70% after treatment
adjustment: ND 36%, NIDD 41% and IDD 43%. In patients with DM and HRPR, there
were no differences in the primary end point rate (15% vs 19%) after treatment
adjustment between patients with an ADP < 70% and with ADP ≥ 70%. HRPR and
IDD resulted independent predictors of the primary end point (HR 1.5 ; p=.032 and
HR 1.4; p=.029 respectively) and cardiac mortality (HR 1.7; p=.013 and HR 1.8;
p=.016). No interaction of HRPR with DM on outcome was found.
Conclusion: HRPR is two-fold higher in IDD as compared to ND. HRPR and IDD
are predictors of long-term clinical outcome in ACS patients receiving PCI. In DM
patients, treatment adjustment with first generation of thienopiridine, has not impact
on outcome. It is unknown if new antithrombotic agents (as prasugrel or ticagrelor)
will provide an improvement on clinical outcome.
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Year Cardiovascular Outcome Among Taiwanese Population Underging
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University, Tainan, Taiwan; 3College of Medicine, National Cheng Kung University,
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Background: Platelet reactivity after clopidogrel therapy varies among individuals.
This study was aimed to evaluate clinical impacts of clopidogrel response variability
and the covariant factors in Asian populations undergoing elective percutaneous
coronary intervention (PCI).
Methods: Patients receiving clopidogrel after elective PCI were prospectively followed
up. Platelet reactivity after clopidogrel therapy was measured with the VerifyNow
P2Y12 assay. The primary endpoints were stent thrombosis and the composite of
cardiac death and non-fatal myocardial infarction (MI) at 2 year.
Results: Among 160 patients (average year of age 62.1±12.9 with 83.5% male in
gender), the average of P2Y12 reaction unit (PRU) was 239.0±85.8 and the average
of inhibition was 0.29±0.22%. Distribution of P2Y12 reaction units (PRU) in this study
cohort was higher than Caucasian reports. Hyporesponders were defined as those with
PRU >275, which was derived from an ROC curve analysis. The background
characteristics were similar in both groups except for diabetes mellitus (DM) (higher
PRU vs. low PRU: 57% vs. 35%; p<0.05). The average PRU of patients with DM was
significantly higher than those without DM (273.7±70.7 vs. 213.2±87.8; p=0.005).
Patients with high PRU levels also had significantly higher rates of both the composite
events (2.4% vs. 0.8%, p=0.04), and stent thrombosis rate (1.8% vs. 0.2%; p=0.03)
compared to normal responders. Multivariable-adjusted analysis showed that PRU
>275 remains an independent predictor of the clinical composite endpoints.
Conclusion: Clopidogrel hypo-responsiveness was significantly associated with
cardiovascular outcome in patients undergoing elective PCI at 2 year. DM contributes
greatly to Asian populations’ platelet reactivity. We should consider ethnic differences
when choosing the cutoff value of PRU.
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Effects of Low Dose Pioglitazone on Restenosis and Atheroma Plaques in
Patients with Diabetes Mellitus Undergoing Percutaneous Coronary
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Background: The insulin-sensitizing agents (rosiglitazone, pioglitazone) reduced
neointimal proliferation in patients with diabetes mellitus (DM) who underwent
percutaneous coronary intervention (PCI) with bare metal stents via the PPAR-r
receptor. We evaluated the clinical outcomes, angiographic results and intravascular
ultrasound (IVUS) results of patients taking pioglitazone after PCI.
Methods: This study was a single center, prospective randomized study. The study
population currently included 121 diabetic patients with coronary artery disease,
assigned to 51 patients taking 15mg of low dose pioglitazone daily in addition to their
diabetic medications and 70 patients without pioglitazone. We have analyzed the
clinical outcomes, angiographic results, IVUS results and the effects on the lipid profile
after 12 months of treatment.
Results: Ninety-seven patients completed follow-up angiography. Among them,
follow-up IVUS was done in fifteen patients. There were no significant differences
between the pioglitazone group and the control group of the baseline clinical
demographics and angiographic findings. The average lesion length and reference
diameter (RD) were 27.2±10.8 mm vs. 27.9±13.2 mm and 2.61±0.46 mm vs. 2.67±0.43
mm in the pioglitazone group and the control group, respectively. After 12 months of
medication, total triglyceride and LDL levels were decreased in the pioglitazone group
compared to control group statistically insignificant. There was no difference of major
cardiac adverse events (MACE), TLR, TVR and The rate of in-stent restenosis(ISR)
between two groups. There were statistically no difference of neointimal volume,
percent neotintmal volume, percent atheroma volume and normalized total atheroma
volume between two groups on IVUS study.
Conclusion: The results of this study showed that low dose pioglitazone, in diabetic
patients who underwent PCI, was not associated with reduced MACE, TLR, non-TVR
and restenosis. And, low dose pioglitazone didn’t affect atheroma plaques and
neointimal proliferation in the stents by IVUS.
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Diabetic Patients Randomized Trial (TITANIC-XV)
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Background: In a roughly 25% of patients (p) Drug Eluting Stents (DES) are not
recommended due to specific clinical reasons that make prolonged use of clopidogrel
not appropriated. A remarkable percentage of these p have diabetes mellitus (DM), a
well known risk factor for stent restenosis. Our aim was to evaluate, in a prospective
randomized trial, whether in DM-p the titanium stent (T), a bioactive bare metal stent
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